Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Two-armed, Parallel, Triple-blind, Active-controlled, Equivalency Clinical Trial of Efficacy and Safety Pertuzumab® (CinnaGen Co.) Compared With Perjeta® (Originator Pertuzumab) in Neoadjuvant Treatment of HER2+ Breast Cancer

NCT04957212 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.

NCT NCT04957212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04957212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Two-armed, Parallel, Triple-blind, Active-controlled, Equivalency Clinical Trial of Efficacy and Safety Pertuzumab® (CinnaGen Co.) Compared With Perjeta® (Originator Pertuzumab) in Neoadjuvant Treatment of HER2+ Breast Cancer
Lead sponsor
Cinnagen
Phase
Phase 3
Overall status
Completed
Start date
August 11, 2018
Completion date
May 27, 2020
Enrollment
214 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer